GeoVax Labs Inc (NASDAQ: GOVX) entered into a license agreement with PNP Therapeutics Inc to develop and commercialize Gedeptin for solid tumors.
The transaction's detailed financial terms were not disclosed but include a combination of upfront payments, milestone fees, and royalties on net sales.
A cycle of therapy consists of three intra-tumoral injections of Gedeptin over two days followed by infusion of a prodrug, fludarabine phosphate, once a day for three days.
A Phase 1 dose-ranging study, evaluating the safety of a single cycle of Gedeptin therapy, found the treatment to be well-tolerated, with evidence of a reduction in tumor size in patients with solid tumors.
A Phase 1/2 trial, evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for injection and no curable treatment options, is currently enrolling.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.